Zhejiang Hisoar Pharmaceutical Co Ltd (002099) — Working Capital to Net Assets Ratio
Zhejiang Hisoar Pharmaceutical Co Ltd (002099) has a Working Capital to Net Assets ratio of 15.6% as of September 2025. Working capital of CN¥799.81 Million (current assets of CN¥2.88 Billion minus current liabilities of CN¥2.08 Billion) is measured against net assets of CN¥5.11 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 002099 equity to assets ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Zhejiang Hisoar Pharmaceutical Co Ltd Working Capital to Net Assets (2003–2024)
This chart shows how Zhejiang Hisoar Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 22 annual periods from 2003 to 2024. As of September 2025, the ratio stands at 15.6%, reflecting working capital of CN¥799.81 Million against net assets of CN¥5.11 Billion CNY. Check 002099 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Zhejiang Hisoar Pharmaceutical Co Ltd (2003–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Zhejiang Hisoar Pharmaceutical Co Ltd from 2003 to 2024, covering 22 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Zhejiang Hisoar Pharmaceutical Co Ltd (002099) total market value.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 12.9% | CN¥662.46 Million | CN¥5.13 Billion | CN¥2.89 Billion | CN¥2.23 Billion | ▼ -1.7 pp |
| 2023 | 14.6% | CN¥818.91 Million | CN¥5.60 Billion | CN¥2.63 Billion | CN¥1.81 Billion | ▼ -6.3 pp |
| 2022 | 20.9% | CN¥1.28 Billion | CN¥6.10 Billion | CN¥3.25 Billion | CN¥1.97 Billion | ▼ -7.0 pp |
| 2021 | 27.9% | CN¥1.70 Billion | CN¥6.11 Billion | CN¥3.44 Billion | CN¥1.73 Billion | ▼ -7.3 pp |
| 2020 | 35.2% | CN¥2.06 Billion | CN¥5.85 Billion | CN¥3.24 Billion | CN¥1.18 Billion | ▼ -1.9 pp |
| 2019 | 37.1% | CN¥2.12 Billion | CN¥5.72 Billion | CN¥3.06 Billion | CN¥940.28 Million | ▼ -2.9 pp |
| 2018 | 40.0% | CN¥2.15 Billion | CN¥5.39 Billion | CN¥3.73 Billion | CN¥1.58 Billion | ▼ -5.7 pp |
| 2017 | 45.7% | CN¥2.35 Billion | CN¥5.14 Billion | CN¥4.54 Billion | CN¥2.18 Billion | ▼ -2.4 pp |
| 2016 | 48.1% | CN¥2.30 Billion | CN¥4.77 Billion | CN¥4.05 Billion | CN¥1.75 Billion | ▲ +24.1 pp |
| 2015 | 24.0% | CN¥859.16 Million | CN¥3.57 Billion | CN¥1.90 Billion | CN¥1.04 Billion | ▲ +9.2 pp |
| 2014 | 14.9% | CN¥472.83 Million | CN¥3.18 Billion | CN¥1.34 Billion | CN¥866.42 Million | ▲ +25.4 pp |
| 2013 | -10.5% | CN¥-66.63 Million | CN¥632.80 Million | CN¥909.11 Million | CN¥975.74 Million | ▼ -35.7 pp |
| 2012 | 25.1% | CN¥185.55 Million | CN¥738.05 Million | CN¥866.83 Million | CN¥681.28 Million | ▼ -17.2 pp |
| 2011 | 42.4% | CN¥312.40 Million | CN¥736.96 Million | CN¥849.01 Million | CN¥536.60 Million | ▲ +6.4 pp |
| 2010 | 36.0% | CN¥229.85 Million | CN¥638.04 Million | CN¥652.70 Million | CN¥422.85 Million | ▲ +6.7 pp |
| 2009 | 29.3% | CN¥164.78 Million | CN¥561.79 Million | CN¥567.25 Million | CN¥402.47 Million | ▲ +7.5 pp |
| 2008 | 21.8% | CN¥119.42 Million | CN¥547.50 Million | CN¥583.64 Million | CN¥464.22 Million | ▼ -11.5 pp |
| 2007 | 33.3% | CN¥179.19 Million | CN¥538.06 Million | CN¥589.55 Million | CN¥410.36 Million | ▼ -5.7 pp |
| 2006 | 39.0% | CN¥202.75 Million | CN¥519.27 Million | CN¥603.01 Million | CN¥400.26 Million | ▲ +39.1 pp |
| 2005 | 0.0% | CN¥-86.28K | CN¥182.96 Million | CN¥386.10 Million | CN¥386.19 Million | ▼ -14.8 pp |
| 2004 | 14.7% | CN¥19.44 Million | CN¥132.03 Million | CN¥236.79 Million | CN¥217.35 Million | ▼ -11.8 pp |
| 2003 | 26.5% | CN¥22.53 Million | CN¥85.03 Million | CN¥228.16 Million | CN¥205.63 Million | — |